知 識 產 權 SinoMab BioScience Limited 中國抗體製藥有限公司 （於香港註冊成立的有限公司） （股份代號：3681） 於 本 公 告 內，「我 們」指 本 公 司，如 文 義 另 有 所 指，本 集 團。 – 1 – 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 告； 所 得 款 項 用 途 變 動； 及 公 司 秘 書 變 動 | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

SINOMAB SinoMab BioScience Limited 中國抗體製藥有限公司 (於香港註冊成立的有限公司) 股份代號 : 3681 中期報告 2022 公司資料 2 主席報告書 3 管理層討論與分析 8 獨立審閱報告 23 中期簡明綜合財務報表 24 中期簡明綜合損益表 24 中期簡明綜合全面收益表 25 中期簡明綜合財務狀況表 26 中期簡明綜合權益變動表 28 中期簡明綜合現金流量表 30 中期簡明綜合財務資料附註 31 42 其他資料 21 釋義 公司資料 | --- | --- | |----------------------------------------------------|--------------------------| | | | | 董事 | 公司秘書 | | 執行董事 | 黃佩彥女士 | | 梁瑞安博士(主席兼首席執行官) | 授權代表 | | 非執行董事 | 梁瑞安博士 | | 陳海剛博士 | 華劍平先生 | | 童汛先生 | | | 劉文溢女士 | 註冊辦事處 | | 劉潔女士 | 香港 | | 石磊先生 | 新界 | | 劉森林先生（已退任，自二零二二年 ...

SINOMAB 6 SinoMab BioScience Limited 中國抗體製藥有限公司 ( 於香港註冊成立的有限公司) 股份代號 : 3681 年度報告 目錄 目 錄 2 公司資料 | --- | --- | --- | |-------|-------|----------------------| | | | | | 3 | | 概要 | | 4 | | 主席報告書 | | 7 | | 生產基地 | | 8 | | 管理層討論與分析 | | | 22 | 董事及管理層 | | | 29 | 企業管治報告 | | | 45 | 環境、社會及管治報告 | | | 78 | 董事會報告 | | | 102 | 獨立核數師報告 | | | 106 | 綜合財務報表 | | | | 106 綜合損益表 | | | | 107 綜合全面收益表 | | | | 108 綜合財務狀況表 | | | | 110 綜合權益變動表 | | | | 111 綜合現金流量表 | | | | 113 財務報表附註 | | | 170 | 釋義 | | | | | 公司資料 | --- | --- | |----------- ...

SinoMab BioScience Limited 中國抗體製藥有限公司 Interim Report 2021 中期報告 （於香港註冊成立的有限公司） 股份代號：3681 中期報告 2021 目 錄 2 公司資料 3 主席報告書 5 管理層討論與分析 18 獨立審閱報告 19 中期簡明綜合財務報表 19 中期簡明綜合損益表 20 中期簡明綜合全面收益表 21 中期簡明綜合財務狀況表 23 中期簡明綜合權益變動表 25 中期簡明綜合現金流量表 26 中期簡明綜合財務資料附註 39 其他資料 49 釋義 公司資料 （已退任，自二零二一年六月十五日起生效） | --- | --- | |------------------------------------------------------------|-----------------------------------------| | | | | 董事 | 公司秘書 | | 執行董事 | 黃佩彥女士 | | 梁瑞安博士 （主席兼首席執行官） | 授權代表 | | 非執行董事 | 梁瑞安博士 | | 陳海剛博士 | 華劍平先生 | | 董汛先生 | | ...

C SINOMAB SinoMab BioScience Limited 中國抗體製藥有限公司 (於香港註冊成立的有限公司) 股份代號: 3681 年度報告 2020 2 GS 目 錄 2 公司資料 | --- | --- | --- | --- | --- | --- | |-------|----------------------|----------------|-------|-------|-------| | | | | | | | | 3 | 摘要 | | | | | | 4 | 主席報告書 | | | | | | 6 | 管理層討論與分析 | | | | | | 17 | 董事及高級管理層 | | | | | | 23 | 企業管治報告 | | | | | | 39 | 環境、社會及管治報告 | | | | | | 76 | 董事會報告 | | | | | | 97 | 獨立核數師報告 | | | | | | 101 | 綜合財務報表 | | | | | | | 101 | 綜合損益表 | | | | | | 102 | 綜合全面收益表 | | | | | | 103 | 綜合財務狀況表 | ...

SinoMab BioScience Limited 中國抗體製藥有限公司 Interim Report 2020 中期報告 SinoMab BioScience Limited 中國抗體製藥有限公司 （於香港註冊成立的有限公司 股份代號：36 81 中期報告 2020 2 GM | --- | --- | --- | --- | --- | --- | |--------|-------|-------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | 目 | | 錄 | | | | | 2 | | 公司資料 | | | | | | | 主席報告書 | | | | | 3 | | | | | | | 5 16 | | 管理層討論與分析 獨立審閱報告 | | | | | | | 中期簡明綜合財務報表 | | | | | 17 | | | | | | | | 17 | 中期簡明綜合損益表 | | | | | | 18 | 中期簡明綜合全面收益表 | | | | | | 19 | 中期簡明綜合財務狀況表 | ...

Financial Performance - The company experienced a loss before tax of RMB 276,282,000 in 2019, compared to a loss of RMB 83,610,000 in 2018, indicating a worsening financial performance [4]. - The total equity of the company reached RMB 1,131,916,000 in 2019, a significant increase from a negative equity of RMB 50,952,000 in 2017 [4]. - Basic and diluted loss per share for the year ended December 31, 2019, was RMB 0.33, compared to RMB 0.12 for 2018, with total losses attributable to equity holders of the parent amounting to RMB 276.3 million in 2019 [44]. - The company's debt-to-equity ratio decreased from 36% as of December 31, 2018, to 2% as of December 31, 2019, indicating improved financial stability [42]. - Other income and gains for the year ended December 31, 2019, totaled approximately RMB 3.0 million, a decrease of about RMB 5.7 million compared to the previous year [37]. Research and Development - The company reported a research and development cost of RMB 214,342,000 for the year ended December 31, 2019, an increase from RMB 47,283,000 in 2018, reflecting a significant investment in innovation [4]. - The company is actively developing new targeted drugs to address unmet medical needs, enhancing its research and innovation capabilities [6]. - The company has a pipeline of 6 investigational drugs covering over 10 indications, demonstrating a strong commitment to expanding its product offerings [6]. - The company is focused on developing innovative therapies for immune diseases, aiming to become a global leader in this field [29]. - The company is committed to reducing R&D timelines and enhancing efficiency, completing the first phase of SAD studies for SN1011 within three months [7]. Product Development and Clinical Trials - The flagship product SM03 has entered Phase III clinical trials for the treatment of rheumatoid arthritis, with plans to submit a new drug application to the US FDA and other regulatory bodies in 2020 [6]. - SM03's Phase III clinical trial for rheumatoid arthritis has recruited 288 patients as of December 31, 2019, with safety data aligning with Phase II results [14]. - The company expects to complete patient recruitment for SM03 by the second half of 2020 and plans to submit a Biologics License Application to the NMPA in the first half of 2021 [14]. - SN1011, a third-generation BTK inhibitor, is undergoing safety and tolerability trials in Australia, with a completed SAD Phase I trial involving 40 participants [16]. - The company plans to submit an IND application for SN1011 targeting autoimmune diseases in China in 2020, although timelines have been extended due to COVID-19 uncertainties [16]. Corporate Governance - The company emphasizes high standards of corporate governance to protect shareholder interests and enhance corporate value since its listing on November 12, 2019 [77]. - The board consists of 11 members, including 2 executive directors, 5 non-executive directors, and 4 independent non-executive directors [80]. - The company has maintained compliance with listing rules by appointing at least three independent non-executive directors, representing one-third of the board [81]. - The board is responsible for leading and monitoring the company, ensuring effective internal controls and risk management systems are in place [83]. - The company has established a director and officer liability insurance policy, which is reviewed annually [84]. Environmental, Social, and Governance (ESG) Initiatives - The company’s environmental, social, and governance (ESG) report covers its performance in these areas for the year 2019, emphasizing the importance of stakeholder concerns [121]. - The company has established a comprehensive quality management system to ensure compliance with GMP standards and product safety [135]. - The company emphasizes community investment and social responsibility as part of its ESG initiatives [130]. - The company has implemented strict supplier qualification audits, ensuring that suppliers can consistently provide high-quality materials and comply with legal regulations [148]. - The company is committed to integrating sustainable development principles into its operations to enhance ESG management [123]. Employee and Workforce Management - The company has a total of 112 employees as of December 31, 2019, emphasizing the importance of human resources for sustainable operations [26]. - The workforce composition includes 48% male employees and 52% female employees, indicating a balanced gender representation [154]. - Employee activities are organized to enhance team cohesion and improve employee satisfaction, including various recreational events [157]. - The company has established multiple internal communication channels to gather employee feedback and suggestions, ensuring timely responses [158]. - The company emphasizes employee welfare, providing competitive salaries and various benefits, including medical insurance and annual bonuses [155]. Strategic Development and Market Position - The company is transitioning to a vertically integrated biopharmaceutical company, with a new production facility in Haikou and a second facility in Suzhou expected to be operational in the second half of 2021, featuring three 2,000-liter stainless steel bioreactors [8]. - The company is expanding its footprint in Hong Kong, Haikou, Suzhou, and Australia to meet the growing global demand for quality healthcare [8]. - The company aims to strengthen global collaborations and technological innovations to become a significant player in the global healthcare industry [10]. - The company is focused on diversifying its product portfolio through new product licensing and collaborations, which is reflected in the significant increase in R&D expenditures [39]. - The company has identified significant risks in new drug development, including long development cycles and low success rates, and plans to implement rigorous evaluation processes [192].